BRPI0418845A - uso de compostos de kauranes na fabricação de medicamentos - Google Patents

uso de compostos de kauranes na fabricação de medicamentos

Info

Publication number
BRPI0418845A
BRPI0418845A BRPI0418845-4A BRPI0418845A BRPI0418845A BR PI0418845 A BRPI0418845 A BR PI0418845A BR PI0418845 A BRPI0418845 A BR PI0418845A BR PI0418845 A BRPI0418845 A BR PI0418845A
Authority
BR
Brazil
Prior art keywords
hydroxyl
compounds
methyl
ester
manufacture
Prior art date
Application number
BRPI0418845-4A
Other languages
English (en)
Inventor
We Tan
Original Assignee
We Tan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by We Tan filed Critical We Tan
Publication of BRPI0418845A publication Critical patent/BRPI0418845A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

USO DE COMPOSTOS DE KAURANES NA FABRICAçãO DE MEDICAMENTOS. A invenção refere-se ao uso farmacêutico de compostos de kaurene da fórmula (I) no tratamento e prevenção de doença coronária, acidente vascular cerebral, arritmia e isquemia cerebral etc. Os referidos compostos também têm efeitos protetores significantes contra infarto isquêmico cerebral, em que R¬ 1¬: hidrogênio, hidroxila ou alcóxi, R¬ 2¬: carboxila, carboxilato, haletos de acila, aldeído, metilidroxila, e grupo de éster, acilamida, acila ou éter hidrolisável por carboxila, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬, R¬ 8¬: independentemente, oxigênio, hidroxila, meti-lidroxila, e éster ou grupo de alquiloximetila hidrolisável por metilldroxila, R¬ 7¬: metila, hidroxila e éster ou alquiloximetila hidrolisável por metilidroxila, R¬ 9¬: metileno ou oxigênio.
BRPI0418845-4A 2004-05-19 2004-05-19 uso de compostos de kauranes na fabricação de medicamentos BRPI0418845A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2004/000508 WO2005110383A1 (en) 2004-05-19 2004-05-19 The use of kauranes compounds in the manufacture of medicament

Publications (1)

Publication Number Publication Date
BRPI0418845A true BRPI0418845A (pt) 2007-11-13

Family

ID=35393975

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418845-4A BRPI0418845A (pt) 2004-05-19 2004-05-19 uso de compostos de kauranes na fabricação de medicamentos

Country Status (9)

Country Link
US (1) US9125877B2 (pt)
EP (1) EP1757282B1 (pt)
JP (1) JP2007538016A (pt)
CN (1) CN100508962C (pt)
AU (1) AU2004319792A1 (pt)
BR (1) BRPI0418845A (pt)
CA (1) CA2606472A1 (pt)
MX (1) MXPA06013503A (pt)
WO (1) WO2005110383A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101633609B (zh) * 2009-08-12 2013-11-06 曹庸 一种从山莓叶中分离出的新化合物、制备方法及用途
CN104557530A (zh) * 2013-11-18 2015-04-29 福建医科大学 对映贝壳杉二萜衍生物及其制备方法和应用
WO2016066672A1 (en) * 2014-10-31 2016-05-06 Fresenius Medical Care Deutschland Gmbh Pharmaceutical compositions containing steviosides
WO2016077581A1 (en) * 2014-11-12 2016-05-19 University Of Florida Research Foundation, Inc. Isosteviol triazoles and uses thereof
WO2017041711A1 (en) * 2015-09-10 2017-03-16 Key-Pharma Biomedical Inc. The use of kauranes compounds in the manufacture of medicament for treatment of cardiac hypertropy and pulmonary hypertension
CN109925302A (zh) * 2019-02-18 2019-06-25 东莞市凯法生物医药有限公司 一种使用贝壳杉烷类化合物保护蒽环类抗肿瘤药物心脏毒性的应用
WO2020231956A1 (en) * 2019-05-13 2020-11-19 Key Pharma Biomedical Inc. New kaurane analogues,their preparation and therapeutically uses
CN112472690B (zh) * 2020-11-15 2022-08-16 珠海沅芷健康科技有限公司 一种制备增强CNPase活性的化合物或生物药物的方法用于治疗心脏疾病
CN113845424B (zh) * 2021-10-14 2023-09-12 南京医科大学 右崁醇酯类化合物及其药物用途
CN114917237A (zh) * 2022-05-13 2022-08-19 葛鹏飞 莱苞迪甙a在制备预防和/或治疗脑缺血所致神经元损伤药物中的应用
CN118388348A (zh) * 2024-06-20 2024-07-26 广东工业大学 一种甜菊醇衍生物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002037716A (ja) * 2000-07-24 2002-02-06 Shiseido Co Ltd カウレン類含有組成物、養毛剤及び皮膚外用剤
KR100383149B1 (ko) * 2000-12-12 2003-05-12 한국생명공학연구원 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도
EP1361870A2 (en) * 2001-02-01 2003-11-19 Nutri Pharma ASA A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome

Also Published As

Publication number Publication date
US9125877B2 (en) 2015-09-08
EP1757282B1 (en) 2015-02-25
WO2005110383A1 (en) 2005-11-24
US20100179097A1 (en) 2010-07-15
JP2007538016A (ja) 2007-12-27
CN1997358A (zh) 2007-07-11
EP1757282A1 (en) 2007-02-28
AU2004319792A1 (en) 2005-11-24
CN100508962C (zh) 2009-07-08
MXPA06013503A (es) 2007-06-12
EP1757282A4 (en) 2010-02-10
CA2606472A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
BRPI0418845A (pt) uso de compostos de kauranes na fabricação de medicamentos
Hwu et al. Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation
Mantani et al. Inhibitory effect of Ephedrae herba, an oriental traditional medicine, on the growth of influenza A/PR/8 virus in MDCK cells
Likhitwitayawuid et al. Chemical transformations of oxyresveratrol (trans-2, 4, 3′, 5′-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
AR002974A1 (es) Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista.
DZ3227A1 (fr) Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
BRPI0410260A (pt) composição conjugada para medicamento
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
TNSN08505A1 (fr) Compositions pharmaceutiques stabilisees comprenant de la fesoterodine
DZ3037A1 (fr) Dérivés nouveaux de pyrimidine inhibiteurs de sorbitol déshydrogénase, leur procédéde préparation etcompositions pharmaceutiques les contenant.
DE60138709D1 (de) Analoge der barbitursäure als therapeutische wirkstoffe
Nguyen et al. Homoisoflavanones from Disporopsis aspera
Cömert Önder et al. Antiproliferative activity of Humulus lupulus extracts on human hepatoma (Hep3B), colon (HT-29) cancer cells and proteases, tyrosinase, β-lactamase enzyme inhibition studies
EP2017620A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
BR0008292A (pt) Derivados de mevinolina
CA2305933A1 (fr) Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation
NO20021898L (no) Farmasoytisk sammensetning inneholdende ciclesonid for applikasjon til mukosa
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
BRPI0410840A (pt) derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
DE602004018647D1 (de) Galloylpeptide

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]